Postitive news for marimastat; British Biotech's drug shows promise against nonoperable gastric cancer

Authors :: Fox, Sophia
Source :: Genetic Engineering News. Sept 15, 1999, Vol. 19 Issue 16, p20, 3 p.
Publication Year :: 1999
Abstract: This is a roundup of news about European Union's biotechnology industry. It includes the promising trial result of Marimastat, British Biotech PLC's anticancer drug for gastric cancer treatment. Other news includes marketing agreement for new drugs, and research and development in genetic engineering and biological products.

Subjects :: British Biotech PLC -- Product development
Scotia Holdings PLC -- Product development
Novartis AG -- Research
Imutran PLC -- Research
Cambridge Antibody Technology Group PLC -- Research
LeukoSite Inc. -- Contracts
Ilex Oncology Inc. -- Contracts
Bayer HealthCare Pharmaceuticals -- Contracts
Glaxo Wellcome PLC -- Product discontinuation
Wyeth -- Mergers, acquisitions and divestments
Stagecoach Group PLC -- Investigations
Cyclacel Ltd. -- Finance
Bayer AG -- Product introduction
BioFocus PLC -- Contracts
Roche Holding Ltd. -- Contracts
Warner-Lambert Co. Parke-Davis Pharmaceutical Research Div. -- Contracts
RiboTargets Ltd. -- Contracts
Tepnel Life Sciences -- Mergers, acquisitions and divestments
Nuclyx -- Mergers, acquisitions and divestments
Pharmagene Inc. -- Finance
British Linen Bank Ltd. -- Finance
Kleinwort Benson Group PLC -- Finance
Sanofi-Synthelabo -- Product introduction
Bavarian Nordic Research Institute A/S -- Product development
Oxford Molecular Group PLC -- Product development
Cambridge Antibody Technology Group PLC -- Product development
Pharmaceutical industry
Biological products industry
Biotechnology industry
Business
European Union

Tools